Treatment of vaginal candidosis with tioconazole 2% vaginal cream. 1985

M Leegaard

Six hundred and three women in a contraceptive clinic were examined for the presence of C. albicans in the vagina and questioned about symptoms. Twenty-nine women with C. albicans accompanied by symptoms were treated with tioconazole 2% in a vaginal cream for 3 days, repeated once after an interval of 1 week. The mycological cure rate was 88.5%. At the same time, 34 women with vaginal C. albicans but without symptoms were examined. The spontaneous cure rate in these patients was 58.8%. In the symptomatic group, rectal C. albicans was observed in 56.5% of patients before treatment. After vaginal treatment, a rectal cure rate of 100% was achieved, but with a recurrency frequency after 2-4 weeks of 17.4%. Comparative vaginal recurrency frequency was 10.3%. Three were not cured. The method used has shown itself to be very acceptable for the patient and to have a cure frequency that is fully equal to previously used, longer lasting treatments.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002181 Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Moniliasis, Vulvovaginal,Vaginitis, Monilial,Candidiasis, Genital,Genital Vulvovaginal Candidiasis,Vaginal Yeast Infection,Vaginal Yeast Infections,Candidiasis, Genital Vulvovaginal,Genital Candidiasis,Infection, Vaginal Yeast,Infections, Vaginal Yeast,Monilial Vaginitis,Vulvovaginal Candidiasis,Vulvovaginal Candidiasis, Genital,Vulvovaginal Moniliasis,Yeast Infection, Vaginal,Yeast Infections, Vaginal
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014622 Vaginal Creams, Foams, and Jellies Medicated dosage forms for topical application in the vagina. A cream is a semisolid emulsion containing suspended or dissolved medication; a foam is a dispersion of a gas in a medicated liquid resulting in a light, frothy mass; a jelly is a colloidal semisolid mass of a water soluble medicated material, usually translucent. Vaginal Creams, Foams and Jellies,Vaginal Cream,Vaginal Creams,Vaginal Foam,Vaginal Foams,Vaginal Gel,Vaginal Jellies,Vaginal Jelly,Vaginal Tablet,Vaginal Tablets,Cream, Vaginal,Creams, Vaginal,Foam, Vaginal,Foams, Vaginal,Gel, Vaginal,Gels, Vaginal,Jellies, Vaginal,Jelly, Vaginal,Tablet, Vaginal,Tablets, Vaginal,Vaginal Gels

Related Publications

M Leegaard
January 1986, The Journal of international medical research,
M Leegaard
February 1978, European journal of obstetrics, gynecology, and reproductive biology,
M Leegaard
March 1983, European journal of obstetrics, gynecology, and reproductive biology,
Copied contents to your clipboard!